2 Phase III trials will be ongoing after great ASCO data from the completed Phase II, which show ORR even as high as 41% when FDA looks for 11% to approve. also much higher than currently approved drugs or ones being tested like KERX for example, SNSS much better results, yet KERS is at $5 range today!
also GENZ had lower ORR and OS rate after Phase II, yet Genzyme(a multi billion$ company) tried to apply for FDA approval straight after Phase II! SNSS drug even stronger than GENZ!
and very safe drug compared to whats being tested and or used currently
If they successfully complete Phase III, and that is a very big if, then the share price will probably jump to $10 to $15. But that won't happen this year. If they start enrolling in the second half of 2010, the results won't be out until late 2011, at the earliest.